|
Market Closed -
Nasdaq
21:00:00 05/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 243.93 USD | -4.14% |
|
-2.29% | +38.60% |
| 10-29 | Biogen Presents New Data Across Alzheimer?S Disease Portfolio At CTAD 2026 | CI |
| 10-29 | Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says | MT |
Company Valuation: Biogen Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,242 | 39,877 | 37,495 | 22,283 | 25,818 | 36,058 | - | - |
| Change | - | 13.15% | -5.97% | -40.57% | 15.86% | 39.66% | - | - |
| Enterprise Value (EV) 1 | 37,820 | 40,560 | 43,384 | 26,204 | 28,289 | 41,692 | 39,139 | 36,460 |
| Change | - | 7.24% | 6.96% | -39.6% | 7.96% | 47.38% | -6.12% | -6.84% |
| P/E | 23.1x | 13.3x | 32.5x | 13.7x | 20x | 45.6x | 21.9x | 17.9x |
| PBR | 3.26x | 3.02x | 2.53x | 1.33x | 1.42x | 1.9x | 1.72x | 1.56x |
| PEG | - | 0x | -0.5x | 0.3x | -0.9x | -1.2x | 0x | 0.8x |
| Capitalization / Revenue | 3.21x | 3.92x | 3.81x | 2.3x | 2.61x | 3.42x | 3.35x | 3.25x |
| EV / Revenue | 3.44x | 3.99x | 4.41x | 2.71x | 2.86x | 3.96x | 3.64x | 3.28x |
| EV / EBITDA | 9.13x | 11.2x | 14.3x | 7.1x | 7.82x | 15x | 11.5x | 10.1x |
| EV / EBIT | 10.3x | 13.1x | 17x | 8.69x | 9.97x | 16.5x | 12.3x | 10.6x |
| EV / FCF | 11.2x | 35.5x | 34.2x | 9.63x | 13.8x | 21.9x | 16.5x | 13.2x |
| FCF Yield | 8.94% | 2.82% | 2.93% | 10.4% | 7.25% | 4.56% | 6.05% | 7.56% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 10.4 | 20.87 | 7.97 | 11.18 | 8.79 | 5.353 | 11.12 | 13.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10,982 | 10,173 | 9,836 | 9,676 | 9,891 | 10,529 | 10,763 | 11,105 |
| EBITDA 1 | 4,144 | 3,618 | 3,040 | 3,689 | 3,618 | 2,786 | 3,397 | 3,593 |
| EBIT 1 | 3,656 | 3,099 | 2,545 | 3,015 | 2,838 | 2,522 | 3,191 | 3,446 |
| Net income 1 | 1,556 | 3,047 | 1,161 | 1,632 | 1,293 | 788 | 1,787 | 2,168 |
| Net Debt 1 | 2,578 | 683 | 5,888 | 3,921 | 2,471 | 5,634 | 3,081 | 402.3 |
| Reference price 2 | 239.92 | 276.92 | 258.77 | 152.92 | 175.99 | 243.93 | 243.93 | 243.93 |
| Nbr of stocks (in thousands) | 146,893 | 144,001 | 144,898 | 145,719 | 146,702 | 147,820 | - | - |
| Announcement Date | 03/02/22 | 15/02/23 | 13/02/24 | 12/02/25 | 06/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 45.57x | 3.96x | 14.96x | -.--% | 36.06B | |
| 39.94x | 13.51x | 30.01x | 0.5% | 1,216B | |
| 39.86x | 6.69x | 18.83x | 1.96% | 656B | |
| 37.08x | 8.43x | 17.39x | 2.4% | 509B | |
| 21.12x | 5.13x | 12.77x | 2.56% | 384B | |
| 97.32x | 5.95x | 25.36x | 2.32% | 362B | |
| 23.5x | 6.02x | 14.53x | 2.65% | 311B | |
| 24.85x | 4.96x | 13.98x | 1.76% | 293B | |
| 28.41x | 7.33x | 12.69x | 2.19% | 249B | |
| -40.11x | 7.32x | 45.99x | 1.97% | 208B | |
| Average | 31.75x | 6.93x | 20.65x | 1.83% | 422.39B | |
| Weighted average by Cap. | 35.96x | 8.53x | 22.17x | 1.71% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BIIB Stock
- Valuation Biogen Inc.
Select your edition
All financial news and data tailored to specific country editions
